Abstract：Objective To investigate the changes and significance of serum transforming growth factor beta 1（TGF- beta 1）,interleukin-2 receptor（sIL-2R） and various serum tumor markers before and after radiotherapy in patients with primary liver cancer.Methods Selection of radiotherapy in our hospital of 90 patients with primary liver cancer（HCC group） and 90 cases of normal people were selected as control group,time of collection in March 2014~September 2016,liver cancer patients were treated by three-dimensional conformal radiation therapy,detection of TGF-before and after radiotherapy in patients with liver cancer group serum beta 1,sIL-2R,golgin 73（GP73）,alpha fetoprotein（AFP）,carcinoembryonic antigen（CEA） and compared with the control group,the subgroup analysis according to different clinical effects.Results Liver cancer group before and after treatment,the serum TGF-,sIL-2R,GP73 beta 1,AFP and CEA levels were significantly higher than the control group,the difference was statistically significant（P<0.05）;liver cancer patients 5 patients withdrew from the study,after treatment,liver TGF-serum beta 1,sIL-2R,GP73,AFP,the level of CEA before treatment were significantly decreased（P<0.05）;90 cases of liver cancer patients,5 cases achieved CR,PR in 52 patients,20 cases of SD patients,8 PD patients;before treatment,patients in group CR+PR and group SD+PD patients serum TGF- beta 1,sIL-2R,GP73,AFP,CEA the level of the difference was statistically significant（P>0.05）;after treatment,the patients in the CR+PR group serum TGF- beta 1,sIL-2R,GP73,AFP and CEA were significantly lower than in group SD+PD（P<0.05）.Conclusion The levels of serum TGF-,sIL-2R,GP73,AFP,and CEA in patients with primary liver cancer were significantly higher than those of patients with primary liver cancer,and were closely related to the effect of radiotherapy.
王静. 血清TGFβ1、sIL-2R及肿瘤标记物在肝癌放射治疗前后的变化及其意义[J]. 哈尔滨医药, 2021, 41(1): 22-24.
Wang, Jing. Changes and Significance of Serum TGF beta 1,sIL-2R and Tumor Markers Before and After Radiotherapy in Patients With Hepatocellular Carcinoma. journal1, 2021, 41(1): 22-24.
[1] Avenaud P,Marais AL,Le BB,et al.Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma[J].Cancer,2015,89(7):1431-1439.
[2] 马清,贾茹,张春艳,等.肝癌患者外周血中循环肿瘤细胞的检测及其应用[J].山东医药,2016,56(19):19-21.
[3] 董辉,丛文铭.提高肝癌规范化病理诊断水平,为临床精细化治疗保驾护航——《原发性肝癌规范化病理诊断指南(2015年版)》解读[J].中国普通外科杂志,2016,25(7):939-943.
[4] 陆录,钦伦秀.美国癌症联合委员会肝癌分期系统(第8版)更新解读[J].中国实用外科杂志,2017,37(2):141-145.
[5] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[6] 周家琛,郑荣寿,庄贵华,等.2000—2015年中国肿瘤登记地区胃癌发病趋势及年龄变化[J].实用肿瘤学杂志,2020,34(1):1-5.
[7] 芦东徽,唐隽,周俊平,等.三维适形放射治疗联合经皮肝动脉化疗栓塞不同序贯顺序治疗原发性肝癌伴门静脉癌栓的临床对照[J].中华肝脏病杂志,2015,23(3):184-188.
[8] 吴惠珍,李霄,吴恩昊,等.血清肿瘤标记物变化对预测肝癌术后的生存价值的研究[J].中国临床药理学杂志,2017,33(13):1201-1204.
[9] 宋培军,刘会春,周磊,等.原发性肝癌患者血清IGF-Ⅱ、TGF-β1及IL-10的检测及意义[J].实用医学杂志,2015,31(24):4040-4042.
[10] 袁星星,姜菲菲,贾泳梅,等.血清铁蛋白和甲胎蛋白及甲胎蛋白异质体-L3单项与联合检测对原发性肝癌辅助诊断的临床应用价值[J].中华检验医学杂志,2016,39(8):604-608.
2021, Vol. 41 
